Recombinant Human Adenovirus- p53 Therapy for the Treatment of Oral Leukoplakia and Oral Squamous Cell Carcinoma: A Systematic Review
- PMID: 34062896
- PMCID: PMC8147319
- DOI: 10.3390/medicina57050438
Recombinant Human Adenovirus- p53 Therapy for the Treatment of Oral Leukoplakia and Oral Squamous Cell Carcinoma: A Systematic Review
Abstract
Background and Objectives: Oral cancer is the 6th most common cancer in the world and oral leukoplakia is an oral potentially malignant disorder that could develop into oral cancer. This systematic review focusses on randomized clinical trials for recombinant adenovirus p-53 (rAD-p53) therapy for the treatment of oral leukoplakia and cancer. Materials and Methods: We searched for research articles on various databases such as Pubmed/Medline, Embase, CNKI (China National Knowledge Infra-structure), Springerlink, cochrane and Web of sciences from 2003 to 2020. MeSH (Medical Subject Headings) terms were used for the search. Inclusion criteria included original research, randomized clinical trials and articles only in English language. Exclusion criteria were any articles that were not research articles, not randomized trials, non-human studies, etc. The articles were further graded on the Jadad scale. Results: 578 articles were assessed from various databases; only 3 articles were found to be appropriate for this review. Thus, meta-analysis was not performed because of heterogeneity and lack of data. In the three studies, whether rAD-p53 was used as a standalone therapy or with other therapies, there was a beneficial effect of the therapy. Furthermore, there were no serious adverse events and the only adverse events reported were fever, pain at the local injection site, flu-like symptoms and lowered WBC count. Conclusions: Thus, we can conclude that this therapy has a potential for beneficial therapeutic effects and further clinical trials with more patients need to be performed to get better understanding of the effect of rAD-p53 therapy, which probably will pave the way to its approval in other parts of the world.
Keywords: gendicine; gene therapy; oral Leukoplakia; oral squamous cell carcinoma; rAD-p53 therapy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Eliciting adverse effects data from participants in clinical trials.Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2. Cochrane Database Syst Rev. 2018. PMID: 29372930 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.Cochrane Database Syst Rev. 2001;(3):CD003234. doi: 10.1002/14651858.CD003234. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003234. doi: 10.1002/14651858.CD003234.pub2. PMID: 11687058 Updated.
-
Interventions for infantile haemangiomas of the skin.Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD006545. doi: 10.1002/14651858.CD006545.pub3. Cochrane Database Syst Rev. 2018. PMID: 29667726 Free PMC article.
Cited by
-
Chromatin structure and gene transcription of recombinant p53 adenovirus vector within host.Front Mol Biosci. 2025 Feb 28;12:1562357. doi: 10.3389/fmolb.2025.1562357. eCollection 2025. Front Mol Biosci. 2025. PMID: 40092712 Free PMC article.
-
Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.Viruses. 2021 Jun 29;13(7):1271. doi: 10.3390/v13071271. Viruses. 2021. PMID: 34209981 Free PMC article. Review.
-
p53 dry gene powder enhances anti-cancer effects of chemotherapy against malignant pleural mesothelioma.Gene Ther. 2024 Mar;31(3-4):119-127. doi: 10.1038/s41434-023-00424-y. Epub 2023 Oct 13. Gene Ther. 2024. PMID: 37833562
-
Genome Engineering as a Therapeutic Approach in Cancer Therapy: A Comprehensive Review.Adv Genet (Hoboken). 2024 Feb 5;5(1):2300201. doi: 10.1002/ggn2.202300201. eCollection 2024 Mar. Adv Genet (Hoboken). 2024. PMID: 38465225 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous